A Japanese-American woman in her 80s spent five years communicating in single words, wearing adult diapers, and needing help to dress. Advanced Alzheimer's had stripped away her independence for a decade. Then caregivers gave her 5 grams of psilocybin-containing mushrooms. She sweated through her clothes, fell into a sleep-like state for 19 hours, and woke up speaking in full sentences, recalling her own life story, and recognizing family members she hadn't acknowledged in years. Within weeks, she was walking solo, dressing herself, and continent again. A month later, a second 3-gram dose appeared to sharpen her even further. The case report, published in Frontiers in Neuroscience, reads like Oliver Sacks fan fiction. Sacks documented patients with encephalitis lethargica who suddenly awakened after L-dopa treatment in the 1970s, only to relapse later. This story has that same eerie quality of buried cognition mysteriously surfacing. But the authors are quick to acknowledge what they don't know, which is almost everything. The woman never received biomarker confirmation of Alzheimer's via brain scans or spinal fluid analysis. No standardized cognitive tests bracketed the mushroom sessions. There was no control group, no way to rule out placebo effect or spontaneous fluctuation. Observations came from family members, not neurologists with clipboards. Psilocybin works primarily through the 5-HT2A serotonin receptor, which animal studies suggest can promote dendritic spine growth (the tiny antennae neurons use to communicate) and boost levels of BDNF (brain-derived neurotrophic factor), a protein that helps maintain neural connections. Brain imaging in healthy volunteers shows psilocybin temporarily scrambles the usual rigid boundaries between large-scale brain networks, creating what some researchers call increased "global integration." The theory goes that in a brain ravaged by Alzheimer's, where neurons are dying and protein plaques are choking communication, psilocybin might briefly unlock dormant pathways, letting surviving networks talk to each other in ways they'd forgotten. But that's pure speculation without pre- and post-treatment brain scans. The timing couldn't be more loaded. Clinical trials for psilocybin-assisted therapy in depression have produced the strongest evidence yet that psychedelics belong in modern medicine, with major studies published in the New England Journal of Medicine showing sustained benefit. Smaller trials are exploring anxiety and addiction. Separately, researchers at the University of California, Berkeley are enrolling cognitively healthy adults aged 60 to 85 for a study examining whether synthetic psilocybin affects memory and brain networks in normal aging. That's not testing a dementia treatment, it's establishing baseline safety and biological effects in older brains. The Alzheimer's case is a million miles from that kind of rigor. The risks are not theoretical. Psilocybin can trigger terrifying psychological experiences, especially in people who can't understand what's happening to them. Older adults face heightened risks of falls, cardiovascular events, and dangerous drug interactions. The woman in this case experienced profuse sweating, suspected hyperthermia, and a prolonged unresponsive state that could easily have gone sideways. She got lucky. The report doesn't establish safety, it establishes that one person survived. Chronic inflammation does appear to drive Alzheimer's progression, and some lab work suggests psilocybin has anti-inflammatory properties, but connecting those dots in a human brain is a leap across an empirical canyon. The case raises a haunting possibility that even years into severe dementia, some cognitive abilities might remain temporarily reachable. Whether psilocybin actually unlocked them, or whether caregivers saw what they hoped to see, remains unknown.